Maura Dougherty

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 6

Top Topics

Health Insurance

Metastatic Renal Cell Carcinoma

Metal Organic Framework

Top Venues

JCO oncology practice

This page only lists publications with an associated author ORCID identifier.

Publications

Minkyoung Yoo, Richard E Nelson, Zachary A Cutshall, Maura Dougherty, Manish Kohli
Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective. JCO oncology practice 19 (3) (2023)
Minkyoung Yoo, Richard E Nelson, Zachary A Cutshall, Maura Dougherty, Manish Kohli
Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective. JCO oncology practice 19 (3) (2023)
Minkyoung Yoo, Richard E Nelson, Zachary A Cutshall, Maura Dougherty, Manish Kohli
Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective. JCO oncology practice 19 (3) (2023)
Minkyoung Yoo, Richard E Nelson, Zachary A Cutshall, Maura Dougherty, Manish Kohli
Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective. JCO oncology practice 19 (3) (2023)
Minkyoung Yoo, Richard E Nelson, Zachary A Cutshall, Maura Dougherty, Manish Kohli
Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective. JCO oncology practice (2023)
Minkyoung Yoo, Richard E Nelson, Zachary A Cutshall, Maura Dougherty, Manish Kohli
Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective. JCO oncology practice 19 (3) (2023)